Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Cell Death and Disease Année : 2022

Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases

Résumé

Cell death plays a pivotal role in the maintenance of tissue homeostasis. Key players in the controlled induction of cell death are the Death Receptors (DR). CD95 is a prototypic DR activated by its cognate ligand CD95L triggering programmed cell death. As a consequence, alterations in the CD95/CD95L pathway have been involved in several disease conditions ranging from autoimmune diseases to inflammation and cancer. CD95L-induced cell death has multiple roles in the immune response since it constitutes one of the mechanisms by which cytotoxic lymphocytes kill their targets, but it is also involved in the process of turning off the immune response. Furthermore, beyond the canonical pro-death signals, CD95L, which can be membrane-bound or soluble, also induces non-apoptotic signaling that contributes to its tumor-promoting and pro-inflammatory roles. The intent of this review is to describe the role of CD95/CD95L in the pathophysiology of cancers, autoimmune diseases and chronic inflammation and to discuss recently patented and emerging therapeutic strategies that exploit/block the CD95/CD95L system in these diseases.

Domaines

Cancer
Fichier principal
Vignette du fichier
s41419-022-04688-x.pdf (2.72 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03631097 , version 1 (05-04-2022)

Licence

Paternité

Identifiants

Citer

Vesna Risso, Elodie Lafont, Matthieu Le Gallo. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases. Cell Death and Disease, 2022, 13 (3), pp.248. ⟨10.1038/s41419-022-04688-x⟩. ⟨hal-03631097⟩
32 Consultations
50 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More